Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Interventional Study to Assess the Clinical Performance of the APOL1 Genotyping Clinical Trial Assay in the Intended Use Population and Environment

NCT06839833 is registered in ClinicalTrials.gov with Almac Diagnostic Services LLC as lead sponsor.

NCT NCT06839833
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06839833 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Interventional Study to Assess the Clinical Performance of the APOL1 Genotyping Clinical Trial Assay in the Intended Use Population and Environment
Lead sponsor
Almac Diagnostic Services LLC
Phase
Not applicable
Overall status
Recruiting
Start date
March 6, 2025
Completion date
February 28, 2027
Enrollment
2,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

apol1-mediated kidney disease